Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -22,808 | -10,292 | -54,365 | -47,197 | -32,331 |
| Depreciation Amortization | -3,855 | -1,969 | -6,775 | -5,060 | -3,521 |
| Other Working Capital | 5,994 | 2,236 | -7,361 | 3,439 | 2,406 |
| Other Operating Activity | 6,680 | 3,315 | 9,235 | 6,957 | 4,348 |
| Operating Cash Flow | $-13,989 | $-6,710 | $-59,266 | $-41,861 | $-29,098 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -21,038 | -8,430 | -87,005 | -112,953 | -66,353 |
| PPE Investments | -121 | -83 | -175 | -266 | -223 |
| Investing Cash Flow | $-21,159 | $-8,513 | $-87,180 | $-113,219 | $-66,576 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 803 | 258 | 6,899 | 5,094 | 4,173 |
| Financing Cash Flow | $803 | $258 | $6,899 | $5,094 | $4,173 |
| Beginning Cash Position | 70,971 | 70,971 | 210,518 | 210,518 | 210,518 |
| End Cash Position | 36,626 | 56,006 | 70,971 | 60,532 | 119,017 |
| Net Cash Flow | $-34,345 | $-14,965 | $-139,547 | $-149,986 | $-91,501 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,989 | -6,710 | -59,266 | -41,861 | -29,098 |
| Capital Expenditure | -121 | -83 | -175 | -266 | -223 |
| Free Cash Flow | -14,110 | -6,793 | -59,441 | -42,127 | -29,321 |